Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “buy” rating restated by analysts at TheStreet in a research report issued to clients and investors on Tuesday, Analyst Ratings Network reports.
The analysts wrote, “Bristol-Myers Squibb Company (BMY) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company’s strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Shares of Bristol-Myers Squibb (NYSE:BMY) traded down 1.49% during mid-day trading on Tuesday, hitting $43.11. Bristol-Myers Squibb has a one year low of $30.64 and a one year high of $49.57. The stock’s 50-day moving average is currently $45.25. The company has a market cap of $70.810 billion and a P/E ratio of 53.63.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings data on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by $0.01. The company had revenue of $4.05 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. The company’s quarterly revenue was down 8.9% on a year-over-year basis. Bristol-Myers Squibb has set its FY13 guidance at $1.70-1.78 EPS. On average, analysts predict that Bristol-Myers Squibb will post $1.77 earnings per share for the current fiscal year.
BMY has been the subject of a number of other recent research reports. Analysts at Argus reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note to investors on Monday. They now have a $54.00 price target on the stock. Separately, analysts at JPMorgan Cazenove raised their price target on shares of Bristol-Myers Squibb from $48.00 to $50.00 in a research note to investors on Friday. Finally, analysts at BMO Capital Markets cut their price target on shares of Bristol-Myers Squibb from $52.00 to $48.00 in a research note to investors on Friday. They now have a “market perform” rating on the stock.
One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $45.33.
The company also recently declared a quarterly dividend, which is scheduled for Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Tuesday, July 2nd.
In other Bristol-Myers Squibb news, Director James M. Cornelius sold 5,000 shares of the company’s stock on the open market in a transaction dated Monday, July 29th. The shares were sold at an average price of $43.81, for a total transaction of $219,050.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.